Valproate and the Pregnancy Prevention Programme: exceptional circumstances
- PMID: 30923139
- PMCID: PMC6428457
- DOI: 10.3399/bjgp19X701897
Valproate and the Pregnancy Prevention Programme: exceptional circumstances
Comment in
-
Valproate and the Pregnancy Prevention Programme.Br J Gen Pract. 2019 May;69(682):229. doi: 10.3399/bjgp19X702377. Br J Gen Pract. 2019. PMID: 31023671 Free PMC article. No abstract available.
References
-
- Medicines and Healthcare products Regulatory Agency Valproate use by women and girls. Guidance. MHRA. 2018 https://www.gov.uk/guidance/valproate-use-by-women-and-girls (accessed 28 Feb 2019).
-
- Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–1699. - PubMed
-
- Vajda FJ, O’Brien TJ, Graham JE, et al. Dose dependence of fetal malformations associated with valproate. Neurology. 2013;81(11):999–1003. - PubMed
-
- Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–1034. - PubMed
-
- Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical